General news
| ShowHide Related Items >><< - 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 11/07/22
- SEC Chief Prashant Yerramalli departing Dec. 31, Amanda Fischer to replace
SPY SPDR S&P 500 ETF Trust - 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 11/14/22
- Jana made new buy Freshpet top holding in Q3, also bought Momentive
- 11/07/22
- SEC Chief Prashant Yerramalli departing Dec. 31, Amanda Fischer to replace
SPY SPDR S&P 500 ETF Trust - 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 01/22/23
- Fed sets course for milder interest-rate rise next month, WSJ says
- 11/04/22
- Fed's Evans says smaller rate hikes make sense, Reuters reports
- 10/22/22
- Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says
- 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 01/22/23
- Fed sets course for milder interest-rate rise next month, WSJ says
- 11/04/22
- Fed's Evans says smaller rate hikes make sense, Reuters reports
- 10/22/22
- Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says
SPY SPDR S&P 500 ETF Trust - 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 01/22/23
- Fed sets course for milder interest-rate rise next month, WSJ says
- 11/04/22
- Fed's Evans says smaller rate hikes make sense, Reuters reports
- 10/22/22
- Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/18/23
- What You Missed On Wall Street On Wednesday
- 12/15/22
- What You Missed On Wall Street On Thursday
- 12/15/22
- What You Missed On Wall Street This Morning
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/18/23
- What You Missed On Wall Street On Wednesday
- 12/15/22
- What You Missed On Wall Street On Thursday
- 12/15/22
- What You Missed On Wall Street This Morning
SPY SPDR S&P 500 ETF Trust - 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/18/23
- What You Missed On Wall Street On Wednesday
- 12/15/22
- What You Missed On Wall Street On Thursday
- 12/15/22
- What You Missed On Wall Street This Morning
- 09/23/22
- SPX Option volume on track for 3.25m contracts, 2nd highest on record
SPY SPDR S&P 500 ETF Trust - 08:24 Today
- SPDR S&P 500 ETF Trust: Pivot points
- 01/31/23
- SPDR S&P 500 ETF Trust: Pivot points
- 01/30/23
- SPDR S&P 500 ETF Trust: Pivot points
- 01/27/23
- SPDR S&P 500 ETF Trust: Pivot points
|
Earnings
|
Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Eli Lilly (LLY), consensus $1.81... Merck (MRK), consensus $1.54... Bristol-Myers (BMY), consensus $1.72... Honeywell (HON), consensus $2.51... Estee Lauder (EL), consensus $1.30... Hershey (HSY), consensus $1.77... Sirius XM (SIRI), consensus 8c... Cardinal Health (CAH), consensus $1.14... Quest Diagnostics (DGX), consensus $1.91... Harley-Davidson (HOG), consensus 6c... Penn Entertaiment (PENN), consensus 41c. ShowHide Related Items >><< - 01/27/23
- Eli Lilly says FDA approves Jaypirca
- 01/24/23
- Eli Lilly trading resumes
- 01/24/23
- Eli Lilly trading halted, volatility trading pause
- 01/24/23
- Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park
- 01/27/23
- Merck's Keytruda approved by FDA for non-small cell lung cancer treatment
- 01/26/23
- Merck Animal Health announces FDA approval for Bravecto Chews for Dogs
- 01/25/23
- Merck to stop Phase 3 KEYNOTE-991 trial
- 01/25/23
- Merck reports 'positive' results from Phase 3 KEYNOTE-966 trial
- 01/31/23
- Prothena reports 'positive' topline Phase 1 study results for PRX005
- 01/27/23
- Bristol-Myers announces CHMP opinion recommending approval for Reblozyl
- 01/27/23
- Bristol-Myers' Sotyktu recommended for approval in psoriasis by Europe's CHMP
- 01/26/23
- iVexSol closes $23.8M Series A-3 financing
- 12/19/22
- Honeywell confirms resolutions with DOJ, SEC, Brazil for $203M
- 12/19/22
- Honeywell pays $160M to resolve bribery investigations in U.S., Brazil
- 12/19/22
- Honeywell pays $81M to settle SEC Foreign Corrupt Practices charges
- 12/16/22
- Verra Mobility names Jon Keyser as Chief Legal Officer
- 11/15/22
- Ermenegildo Zegna to enter long term license for Tom Ford with Estee Lauder
- 11/15/22
- Estee Lauder to acquire TOM FORD brand
- 11/02/22
- Estee Lauder raises quarterly dividend 10% to 66c from 60c per share
- 11/01/22
- Mondelez announces three new members to senior management team
- 12/07/22
- Hershey announces first bilingual manufacturing facility
- 10/20/22
- Hershey signs new solar power purchase agreement with National Grid Renewables
- 08/31/22
- Hershey names Marlene Creighton as Global Chief Sales Officer
- 11/01/22
- Sirius XM continues to expect positive 2022 self-pay net subscriber additions
- 11/01/22
- Sirius XM reports Q3 self-pay subscribers 32.3M
- 11/01/22
- Sirius XM raises quarterly cash dividend 10%
- 10/31/22
- Sirius XM to be standard in-dash feature across full lineup of Lucid vehicles
- 12/19/22
- Cardinal Health announces Aaron Alt as chief financial officer
- 12/12/22
- Yellow Corp appoints Annlea Rumfola as CIO
- 11/14/22
- Elliott made Triple Flag Precious Metals top holding during Q3
- 09/15/22
- PayrHealth announces collaboration with Cardinal Health
- 01/23/23
- Agilent, Quest team to extend access to Resolution ctDx FIRST NGS test
- 12/08/22
- Quest Diagnostics partners with Northern Light Health in Maine
- 12/01/22
- Quest Diagnostics awarded group purchasing agreement by Premier
- 11/28/22
- Quest Diagnostics completes acquisition of LabCare
- 01/31/23
- Nevada reports December statewide gaming win up 14.3% to $1.31B
- 12/29/22
- Nevada reports November statewide gaming win down 7.62% to $1.22B
- 12/20/22
- New Jersey reports November gaming revenue up 0.3% to $441.1M
- 12/08/22
- Penn Entertainment announces $750M share buyback program
- 01/20/23 William Blair
- Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
- 01/12/23 Guggenheim
- Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
- 01/03/23 Barclays
- Eli Lilly price target raised to $400 from $395 at Barclays
- 12/23/22 Raymond James
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- 01/26/23 Citi
- Novartis downgraded to Neutral from Buy at Citi
- 01/04/23 BofA
- Merck upgraded to Buy at BofA on consistent revenue upside
- 01/04/23 BofA
- Merck upgraded to Buy from Neutral at BofA
- 01/03/23 Wells Fargo
- Merck price target raised to $125 from $110 at Wells Fargo
- 01/19/23 Piper Sandler
- Amgen price target cut at Piper on lower Otezla estimates
- 01/17/23 Cantor Fitzgerald
- Bristol-Myers initiated with an Overweight at Cantor Fitzgerald
- 12/23/22 William Blair
- NccRCC 'material expansion opportunity' for Exelixis, says William Blair
- 11/17/22 Credit Suisse
- Bristol-Myers initiated with a Neutral at Credit Suisse
- 01/04/23 UBS
- Honeywell downgraded to Sell from Buy at UBS
- 12/09/22 Citi
- Honeywell price target raised to $248 from $213 at Citi
- 12/05/22 Deutsche Bank
- Honeywell price target raised to $242 from $227 at Deutsche Bank
- 12/01/22 Barclays
- Honeywell price target raised to $229 from $212 at Barclays
- 01/31/23 Jefferies
- Bath & Body Works price target raised to $52 from $45 at Jefferies
- 01/24/23 Stifel
- Estee Lauder price target raised to $295 from $255 at Stifel
- 01/23/23 Deutsche Bank
- Estee Lauder price target raised to $290 from $266 at Deutsche Bank
- 01/17/23 Oppenheimer
- Estee Lauder price target raised to $300 from $245 at Oppenheimer
- 01/06/23 Evercore ISI
- Hershey downgraded to In Line from Outperform at Evercore ISI
- 01/03/23 Wells Fargo
- Hershey initiated with an Underweight at Wells Fargo
- 12/20/22 Morgan Stanley
- Hershey price target raised to $231 from $224 at Morgan Stanley
- 12/08/22 UBS
- Hershey upgraded to Buy from Neutral at UBS
- 01/03/23 JPMorgan
- Sirius estimates cut on 'challenged' advertising market at JPMorgan
- 12/01/22 Citi
- Sirius XM downgraded to Sell from Buy at Citi
- 11/02/22 Deutsche Bank
- Sirius XM price target lowered to $7.50 from $8 at Deutsche Bank
- 11/02/22 Pivotal Research
- Sirius XM price target lowered to $6.75 from $7.10 at Pivotal Research
- 01/31/23 UBS
- Cardinal Health price target raised to $91 from $78 at UBS
- 11/22/22 Credit Suisse
- Cardinal Health price target raised to $79 from $64 at Credit Suisse
- 11/14/22 Mizuho
- Cardinal Health price target raised to $74 from $66 at Mizuho
- 11/07/22 Baird
- Cardinal Health price target raised to $82 from $74 at Baird
- 01/23/23 Evercore ISI
- Quest Diagnostics initiated with an In Line at Evercore ISI
- 01/12/23 Baird
- Quest Diagnostics price target raised to $154 from $143 at Baird
- 12/14/22 Mizuho
- Quest Diagnostics price target raised to $165 from $160 at Mizuho
- 11/17/22 Citi
- Quest Diagnostics downgraded to Sell from Neutral at Citi
- 01/20/23 JMP Securities
- Penn Entertainment price target lowered to $45 from $48 at JMP Securities
- 01/11/23 Truist
- Penn Entertainment price target lowered to $36 from $40 at Truist
- 01/09/23 Jefferies
- Penn Entertainment downgraded to Hold at Jefferies as focus narrows
- 01/09/23 Jefferies
- Penn Entertainment downgraded to Hold from Buy at Jefferies
- 12/13/22
- Eli Lilly sees FY23 EPS $8.10-$8.30, consensus $9.15
- 12/13/22
- Eli Lilly backs FY22 EPS view $7.70-$7.85, consensus $7.78
- 11/01/22
- Eli Lilly cuts FY22 EPS view to $7.70-$7.85 from $7.90-$8.05, consensus $7.99
- 11/01/22
- Eli Lilly reports Q3 EPS $1.98, consensus $1.96
- 10/27/22
- Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35
- 10/27/22
- Merck reports Q3 adjusted EPS $1.85, consensus $1.71
- 10/26/22
- Notable companies reporting before tomorrow's open
- 10/26/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
- 10/25/22
- Notable companies reporting before tomorrow's open
- 11/18/22
- Honeywell reaffirms Q4, 2022 guidance after asbestos settlement
- 10/27/22
- Honeywell sees Q4 adjusted EPS $2.46-$2.56, consensus $2.51
- 10/27/22
- Honeywell narrows FY22 adjusted EPS view to $8.70-$8.80 from $8.55-$8.80
- 10/27/22
- Honeywell reports Q3 adjusted EPS $2.25, consensus $2.16
- 11/02/22
- Estee Lauder cuts FY23 adjusted EPS view to $5.25-$5.40. from $7.39-7.54
- 11/02/22
- Estee Lauder sees Q2 adjusted EPS $1.19-$1.29, consensus $2.81
- 11/02/22
- Estee Lauder reports Q1 EPS $1.37, consensus $1.31
- 11/01/22
- Notable companies reporting before tomorrow's open
- 11/04/22
- Hershey raises FY22 adjusted EPS view to $8.20-$8.27 from $8.05-$8.20
- 11/04/22
- Hershey reports Q3 adjusted EPS $2.17, consensus $2.10
- 11/03/22
- Notable companies reporting before tomorrow's open
- 11/03/22
- Notable companies reporting before tomorrow's open
- 11/01/22
- Sirius XM reports Q3 adjusted EPS 7c, consensus 8c
- 11/01/22
- Sirius XM sees FY22 revenue $9B, consensus $9.04B
- 11/01/22
- Sirius XM reports Q3 diluted EPS 6c, consensus 8c
- 10/31/22
- Notable companies reporting before tomorrow's open
- 11/04/22
- Cardinal Health backs FY23 EPS view $5.05-$5.40, consensus $5.24
- 11/04/22
- Cardinal Health reports Q1 EPS $1.20, consensus 94c
- 11/03/22
- Notable companies reporting before tomorrow's open
- 11/03/22
- Notable companies reporting before tomorrow's open
- 10/20/22
- Quest Diagnostics raises FY22 adjusted EPS view to $9.75-$9.95 from $9.55-$9.95
- 10/20/22
- Quest Diagnostics reports Q3 adjusted EPS $2.36, consensus $2.19
- 11/03/22
- Penn Entertainment reports Q3 EPS 72c, consensus 38c
- 11/02/22
- Notable companies reporting before tomorrow's open
- 11/02/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Penn National reports Q2 EPS 15cvs $1.17 last year
- 12/19/22
- Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 10/11/22
- New quality issues found at Eli Lilly drug plant, Reuters reports
- 08/13/22
- Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says
- 01/13/23
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- 01/11/23
- Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says
- 12/30/22
- Merck's Covid treatment gets conditional approval in China, Reuters reports
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 01/04/23
- Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 09/19/22
- Defense companies urged to limit use of Chinese supplies, WSJ reports
- 11/16/22
- Zegna to acquire rest of Tom Ford International, Bloomberg reports
- 11/15/22
- Estee Lauder to acquire Tom Ford in deal valued at $2.8B, WSJ reports
- 11/15/22
- Estee Lauder nearing deal to acquire Tom Ford for $2.8B, WSJ reports
- 11/11/22
- Estee Lauder near deal to acquire Tom Ford for $2.8B, FT reports
- 12/30/22
- Hershey sued over metals content in dark chocolate, Reuters says
- 12/19/22
- Hershey among brands called out by Consumer Reports for lead exposure
- 12/01/22
- Sirius XM to cut staff amid faltering sales growth, Bloomberg reports
- 12/01/22
- Sirius XM to reduce staff in coming weeks, Bloomberg reports
- 08/31/22
- James Van Der Beek sues SiriusXM over podcast deal, THR reports
- 09/22/22
- Activist Elliott would like to see Pinterest put up for sale, Barron's says
- 08/15/22
- Elliott has large stake in Cardinal Health, seeks board seats, WSJ says
- 12/19/22
- Doctors gain confidence in new Alzheimer's blood tests, Bloomberg reports
- 01/23/23
- Biotech Alert: Searches spiking for these stocks today
- 01/20/23
- What You Missed On Wall Street This Morning
- 01/20/23
- Fly Intel: Pre-market Movers
- 12/19/22
- What You Missed On Wall Street On Monday
- 01/12/23
- Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/17/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/17/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/10/22
- Meet Silo Pharma: Fly exclusive interview with CEO Weisblum, VP of R&D Kuo
- 01/04/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/19/22
- What You Missed On Wall Street On Monday
- 11/18/22
- What You Missed On Wall Street On Friday
- 10/27/22
- What You Missed On Wall Street On Thursday
- 12/17/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/10/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/06/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/17/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/07/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 01/03/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/08/22
- What You Missed On Wall Street On Thursday
- 12/08/22
- What You Missed On Wall Street This Morning
- 12/01/22
- What You Missed On Wall Street On Thursday
- 12/01/22
- What You Missed On Wall Street This Morning
- 11/28/22
- Fly Insider: Autoscope, Archer Aviation among week's notable insider trades
- 11/01/22
- Fly Intel: Pre-market Movers
- 11/04/22
- Fly Intel: Pre-market Movers
- 09/28/22
- #SocialStocks: Details of Musk's deposition by Twitter still being hammered out
- 08/15/22
- What You Missed On Wall Street On Monday
- 08/11/22
- Fly Intel: Pre-market Movers
- 01/23/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/19/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 11/17/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/20/22
- Fly Intel: Pre-market Movers
- 01/20/23
- Bet On It: Kentucky lawmaker sees momentum towards sports betting legalization
- 01/13/23
- Bet On It: PlayUp SPAC deal terminated
- 01/09/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/06/23
- Bet On It: Three downstate New York casino licenses now up for grabs
- 11/01/22
- Unusually active option classes on open November 1st
- 10/03/22
- Eli Lilly And Co put volume heavy and directionally bearish
- 09/28/22
- Early notable gainers among liquid option names on September 28th
- 09/28/22
- Unusually active option classes on open September 28th
- 01/10/23
- Largest borrow rate increases among liquid names
- 12/07/22
- Largest borrow rate increases among liquid names
- 11/14/22
- Early notable gainers among liquid option names on November 14th
- 10/10/22
- Early notable gainers among liquid option names on October 10th
- 09/29/22
- Early notable gainers among liquid option names on September 29th
- 09/12/22
- Early notable gainers among liquid option names on September 12th
- 09/12/22
- Unusually active option classes on open September 12th
- 09/08/22
- Notable open interest changes for September 8th
- 01/18/23
- Honeywell put volume heavy and directionally bearish
- 12/21/22
- Early notable gainers among liquid option names on December 21st
- 11/04/22
- Early notable gainers among liquid option names on November 4th
- 11/16/22
- Early notable gainers among liquid option names on November 16th
- 01/05/23
- Largest borrow rate increases among liquid names
- 12/30/22
- Sirius XM call volume above normal and directionally bullish
- 12/22/22
- Sirius XM put volume heavy and directionally bearish
- 12/06/22
- Largest borrow rate increases among liquid names
- 12/02/22
- Early notable gainers among liquid option names on December 2nd
- 11/11/22
- Cardinal Health put volume heavy and directionally bearish
- 10/10/22
- Cardinal Health call volume above normal and directionally bullish
- 08/12/22
- Early notable gainers among liquid option names on August 12th
- 12/14/22
- Penn National call volume above normal and directionally bullish
- 12/09/22
- Unusually active option classes on open December 9th
- 12/08/22
- Penn National put volume heavy and directionally bearish
- 11/14/22
- Penn National call volume above normal and directionally bullish
|